Singapore, Nov 19, 2009: US-based XTend Medical, a company specializing in manufacturing and distributing the latest in telemedicine and diagnostic devices, has announced that the company is in final stages of completing its merger with BioHarp, Korea.

Mr Paul D Lisenby, CEO of XTend Medical said, “While we originally intended to just merge operations, XTend feels it will be in the best interest to purchase the assets wherein the newly merged entity would own the BioHarp medical device in its entirety. This insures the company has sufficient assets for proper company valuation as we look to begin the process of moving to a higher exchange.”

According to the company, this will involve both securities and cash, thus it is imperative to properly investigate any tax implications or other fees that may have an affect on both companies to insure the company is following proper procedures for the regulatory agencies.